Remikiren

Remikiren

Clinical data
ATC code	C09XA01 (WHO)
Pharmacokinetic data
Protein binding	83%
Identifiers
IUPAC name (2R)-2-(tert-butylsulfonylmethyl)-N-[(2S)-1- {[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4- dihydroxybutan-2-yl]amino}-3-(3H-imidazol- 4-yl)-1-oxopropan-2-yl]-3-phenylpropanamide
CAS Number	126222-34-2
PubChem CID	5462340
DrugBank	APRD00163
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C33H50N4O6S
Molar mass	630.839 g/mol

WikiDoc Resources for Remikiren
Articles
Most recent articles on Remikiren Most cited articles on Remikiren Review articles on Remikiren Articles on Remikiren in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Remikiren Images of Remikiren Photos of Remikiren Podcasts & MP3s on Remikiren Videos on Remikiren
Evidence Based Medicine
Cochrane Collaboration on Remikiren Bandolier on Remikiren TRIP on Remikiren
Clinical Trials
Ongoing Trials on Remikiren at Clinical Trials.gov Trial results on Remikiren Clinical Trials on Remikiren at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Remikiren NICE Guidance on Remikiren NHS PRODIGY Guidance FDA on Remikiren CDC on Remikiren
Books
Books on Remikiren
News
Remikiren in the news Be alerted to news on Remikiren News trends on Remikiren
Commentary
Blogs on Remikiren
Definitions
Definitions of Remikiren
Patient Resources / Community
Patient resources on Remikiren Discussion groups on Remikiren Patient Handouts on Remikiren Directions to Hospitals Treating Remikiren Risk calculators and risk factors for Remikiren
Healthcare Provider Resources
Symptoms of Remikiren Causes & Risk Factors for Remikiren Diagnostic studies for Remikiren Treatment of Remikiren
Continuing Medical Education (CME)
CME Programs on Remikiren
International
Remikiren en Espanol Remikiren en Francais
Business
Remikiren in the Marketplace Patents on Remikiren
Experimental / Informatics
List of terms related to Remikiren

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.